Apprentice Raises $100 Million to Adapt Pharma Supply Chains to the Omicron Variant
Apprentice, the company helping pharma manufacturers get medicine to patients faster, announced today that it raised $100 million in Series C funding led by new investor Alkeon Capital Management, with repeat participation from Silverton Partners, Insight Partners, Pacific Western Bank, and new investment by Colorcon Ventures. The company will use the capital to help pharma manufacturers harden their supply chains to keep making patient-critical drugs and adapt vaccines to meet the evolving strains of COVID-19.
How Augmented Reality Strengthens Biotech Manufacturing
Probably, the biggest advantage of AR is it enables seeing the production process virtually, without the need to be there. “It’s a game-changer for the industry. Individuals can have eyes and ears on site at a moment’s notice to address an emerging issue, or to host routine remote collaboration sessions,” Stracquatanio highlights.
AR can also increase control over the manufacturing process. Pharma and biotech companies cannot afford mistakes during the production phase. A little oversight might lead to serious consequences such as having to start from scratch, which can be very expensive and time-consuming. A recent example is that of Johnson & Johnson’s manufacturing partner Emergent BioSolutions, whose workers erroneously mixed ingredients from two different Covid-19 vaccines; this led to wasting around 15 million vaccine doses.
During a working day, we could see an operator who loads 3D models of biotech instruments, looking at specific pieces and relevant information appearing in the smart glasses or tablet. Meanwhile, another engineer walks up to a machine with a QR code, and instructions pop up in the glasses, facilitating access to the adjustments. A few steps from there, another colleague is looking at batch records, saving values into the system just via voice.
Apprentice.io Gains Funding for AR & AI-Driven Software Platform to Meet COVID-19 Pharma Demands
Bringing a drug to market is an incredibly complex process that requires many stakeholders. The ability of these stakeholders to collaborate in the lab or manufacturing suite has been exceptionally difficult due to the pandemic. Apprentice site deployments have increased 6x since March due to their ability to provide a secure platform for pharma teams, subject matter experts, suppliers, FAT-SAT sites and contracted partners to connect and troubleshoot remotely, moving product development along efficiently.